Novus Therapeutics (NASDAQ:NVUS) versus Ono Pharmaceutical (NASDAQ:OPHLF) Financial Contrast

Share on StockTwits

Novus Therapeutics (NASDAQ:NVUS) and Ono Pharmaceutical (OTCMKTS:OPHLF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Novus Therapeutics and Ono Pharmaceutical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novus Therapeutics 0 0 1 0 3.00
Ono Pharmaceutical 0 0 0 0 N/A

Novus Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 1,171.46%. Given Novus Therapeutics’ higher possible upside, equities analysts plainly believe Novus Therapeutics is more favorable than Ono Pharmaceutical.

Earnings and Valuation

This table compares Novus Therapeutics and Ono Pharmaceutical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novus Therapeutics N/A N/A -$14.06 million ($1.56) -0.50
Ono Pharmaceutical $2.60 billion 3.60 $464.98 million N/A N/A

Ono Pharmaceutical has higher revenue and earnings than Novus Therapeutics.

Profitability

This table compares Novus Therapeutics and Ono Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novus Therapeutics N/A -100.64% -88.15%
Ono Pharmaceutical 17.90% 9.25% 8.17%

Risk & Volatility

Novus Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Institutional and Insider Ownership

26.9% of Novus Therapeutics shares are owned by institutional investors. 5.7% of Novus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Ono Pharmaceutical beats Novus Therapeutics on 6 of the 11 factors compared between the two stocks.

About Novus Therapeutics

Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company's products include OPDIVO intravenous infusions for treating malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Glactiv and FORXIGA tablets for type II diabetes; Kinedak tablets to treat diabetic peripheral neuropathy; Recalbon tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease treatment; Onoact injections for the treatment of tachyarrhythmia; Staybla tablets for overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; Onon capsules and dry syrups for the treatment of bronchial asthma and allergic rhinitis; and Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis. It is also developing products for gastric, colorectal, small and non-small cell lung, head and neck, urothelial, esophageal, ovarian, biliary tract, hematologic cancers; and hodgkin lymphoma, hepatocellular carcinoma, glioblastoma, malignant pleural mesothelioma, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, solid tumor, central nervous system lymphoma, primary testicular lymphoma, virus positive/negative solid carcinoma, chronic myeloid leukemia, cancer anorexia/cachexia, melanoma, pheochromocytoma, acute leukemia, juvenile idiopathic arthritis, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, tachyarrhythmia, ventricular arrhythmia, sepsis, hepatitis C, parkinson's disease, overactive bladder, osteoarthritis, sjögren syndrome, and underactive bladder. Ono Pharmaceutical Co., Ltd. has collaboration agreements with Eisai Co., Ltd. and Schrödinger Inc., and Merus N.V. The company was founded in 1717 and is headquartered in Osaka, Japan.

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.